Wockhardt Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 14 Jun 2026 | Market Cap: ₹32.6K Cr
Future growth expectations for Wockhardt Limited as per the document include: - Slow initial increase in revenue from new molecules like Zaynich, with a hockey-stick growth trajectory expected after 12-18 months. Wockhardt expects a significant growth trajectory in revenue and profitability over the next 12-18 months, especially from the novel antibiotic business like Zaynich, with a "hockey stick" growth pattern post initial commercialization phase.
From Wockhardt Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,886
Market Cap
₹32.6K Cr
P/E Ratio
114.8
Revenue Rank
Margin Rank
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹965 Cr, net profit ₹164 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2📈 Profitability & Margins
Rank 3- →Wockhardt expects a significant growth trajectory in revenue and profitability over the next 12-18 months, especially from the novel antibiotic business like Zaynich, with a "hockey stick" growth pattern post initial commercialization phase.
- →Initial 12-18 months may see minor losses or breakeven in the novel antibiotic segment due to upfront investment in organization building.
- →The company projects growing biosimilar business, with expectations to double capacity and sales in 24-36 months, especially in diabetes biosimilars.
- →EBITDA margin has improved substantially from 5.4% three years ago to about 19% currently, reflecting focus on profitability.
- →Capex in the next three years is expected around INR 200-300 crores, mainly for biologicals and R&D.
- →Long-term, Wockhardt targets 20-25% market share in resistant infections and steady growth in India and emerging markets.
- →Overall, profitability and EPS are anticipated to improve markedly as new drugs scale globally after initial investments.
🏗️ Capital Expenditure Plans
Yes- →Planned capex over next three years: INR 200 to 300 crores, mainly for expanding biologicals capacity (Page 14).
- →Investment in increasing biosimilar capacity, aiming to double capacity within 12 to 15 months (Page 26).
- →Continued R&D spends at a consistent percentage of sales to support product pipeline development (Page 14).
- →Focus on building a new business model and organizational capabilities for commercialization of innovative drugs like Zaynich, involving upfront revenue costs rather than capex (Page 14).
- →Investment in building an organization to sell antibiotics worldwide over next 2-3 years (Page 19).
- →Asset-light approach used in international markets by partnering for operational aspects outside India and US to reduce capital-heavy investments (Page 14, Page 26).
💰 Fundraising & Capital Structure
No information- →There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript.
- →Dr. Habil Khorakiwala highlighted that the company is in a "fairly healthy position" financially with adequate liquidity and does not foresee a need for acquisitions or external fundraising for growth in the next 10-20 years.
- →The focus is on organic growth through their pipeline of molecules, especially antibiotics like Zaynich.
- →Prior liquidity challenges have been addressed through past measures like QIPs and debt restructuring, with the company now enjoying strong profitability and low net debt-to-equity (0.1).
- →Capex for the next 2-3 years expected around INR 200-300 crores, primarily for biologicals and R&D, funded from internal accruals.
- →For commercial expansion (e.g., US market), initial operational costs and possible minor losses for 12-18 months are anticipated but funded internally.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Wockhardt Ltd Q4 FY26 results?
Future growth expectations for Wockhardt Limited as per the document include: - Slow initial increase in revenue from new molecules like Zaynich, with a hockey-stick growth trajectory expected after 12-18 months. Wockhardt expects a significant growth trajectory in revenue and profitability over the next 12-18 months, especially from the novel antibiotic business like Zaynich, with a "hockey stick" growth pattern post initial commercialization phase.
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 114.8 with a market cap of ₹32,598 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wockhardt Ltd planning capital expenditure?
Planned capex over next three years: INR 200 to 300 crores, mainly for expanding biologicals capacity (Page 14).
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.